What did @.beautybybokhari actually say?
Dr. Bokhari, a self-described board-certified cardiologist, told 1.4 million viewers that semaglutide "not only does weight loss, but also reduces one's risk of having a heart attack, stroke, or death by 20%." He credited a study called SELECT, described it as involving 17,000 patients across 41 countries and 800 centers, and said it was "just published earlier this month." He also correctly noted semaglutide's approval history: 2017 for diabetes, 2021 as a weight-loss agent.
He opened with a somewhat confusing line, telling viewers "don't take semaglutide if you want to lose weight fast," then pivoted to explaining it suppresses appetite and aids weight control. That framing was a little muddled, but the main thrust of the video was the cardiovascular claim, which deserves a serious look.
Does the science back this up?
Yes, with important caveats. The SELECT trial is real, rigorous, and the 20% figure is accurate, but it applies to a specific population that most TikTok viewers probably are not in.
SELECT (Lincoff et al., 2023, New England Journal of Medicine) enrolled 17,604 adults with pre-existing cardiovascular disease, overweight or obesity, but without diabetes. Participants received weekly semaglutide 2.4 mg or placebo. Over a median follow-up of 33 months, semaglutide reduced the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72-0.90). That is a statistically robust finding from a well-powered randomized controlled trial. The 41-country, 800-site scale he cited checks out.
What the video does not say: every participant already had established cardiovascular disease. SELECT was not testing semaglutide in healthy people trying to lose weight. The benefit in people without prior heart disease is unknown from this trial specifically.
What did they get wrong (or right)?
The approval dates he gave were slightly off. Semaglutide was approved by the FDA for type 2 diabetes as Ozempic in December 2017. That is accurate. But the weight-loss formulation, Wegovy, was approved in June 2021. He said "2021 as a weight loss agent," which is close enough to call correct.
He also said it is "marketed as a zombic" and "why gov" in what is clearly a pronunciation stumble on Ozempic and Wegovy. Forgivable in a casual video format, but worth flagging because medication names matter for patients searching online.
The bigger issue is context omission, not factual error. Saying semaglutide reduces cardiovascular risk by 20% without specifying it was in high-risk patients with existing heart disease is the kind of shortcut that turns a nuanced clinical finding into a sweeping marketing claim. Plenty of viewers will hear this and assume semaglutide protects anyone's heart. SELECT does not support that interpretation. To his credit, Dr. Bokhari did not claim semaglutide cures heart disease, and he cited the actual study by name, which is more than most health influencers do.
What should you actually know?
The SELECT trial is genuinely significant. It was the first large randomized trial to show a GLP-1 receptor agonist reduced major cardiovascular events in non-diabetic patients with obesity and established heart disease. That is a meaningful advance. Researchers are still working out whether the benefit comes from weight loss itself, direct effects of semaglutide on the cardiovascular system, or both. A 2024 analysis published in Nature Medicine (Nissen et al., 2024) suggested the cardiovascular benefit appeared early, before significant weight loss occurred, pointing toward mechanisms beyond just fat reduction.
If you do not have pre-existing cardiovascular disease, the SELECT data does not directly apply to you. That does not mean semaglutide has no cardiovascular benefit for lower-risk individuals, it means we do not yet have the evidence to say one way or another. And semaglutide is not a fast weight-loss drug, Dr. Bokhari actually said as much, though he buried it. Average weight loss in SELECT was around 10% of body weight over about three years.
- Semaglutide is FDA-approved for weight management (Wegovy) and type 2 diabetes (Ozempic). They are not interchangeable products.
- The 20% cardiovascular risk reduction in SELECT applied only to patients with existing cardiovascular disease and obesity or overweight without diabetes.
- Semaglutide is a prescription medication with real side effects including nausea, pancreatitis risk, and potential thyroid concerns. It requires medical supervision.
- Compounded semaglutide is not the same as FDA-approved brand-name products and carries different risk and quality considerations.